Abstract
A 27-year-old female with acute intermittent porphyria presented in a life-threatening acute attack. She developed a Staphylococcus aureus septicaemia and was treated with intravenous vancomycin for 4 weeks. Porphyrins and their precursors were monitored and declined during the course of therapy. The safety of vancomycin in people with the acute porphyrias has not previously been documented, and we conclude that, in this case, the use of vancomycin was without ill-effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Day R. S., Pimstone N. R., Eales L. The diagnostic value of blood plasma porphyrin methyl ester profiles produced by quantitative TLC. Int J Biochem. 1978;9(12):897–904. doi: 10.1016/0020-711x(78)90067-8. [DOI] [PubMed] [Google Scholar]
- MAUZERALL D., GRANICK S. The occurrence and determination of delta-amino-levulinic acid and porphobilinogen in urine. J Biol Chem. 1956 Mar;219(1):435–446. [PubMed] [Google Scholar]
- Neilson I. R., Chaykowski F. T., Singer M. A., Marks G. S. A possible association between membrane-fluidizing properties and porphyrin-inducing activity of drugs. Biochem Pharmacol. 1979 Dec 15;28(24):3589–3593. doi: 10.1016/0006-2952(79)90404-0. [DOI] [PubMed] [Google Scholar]
- Piepkorn M. W., Hamernyik P., Labbé R. F. Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical interpretation. Clin Chem. 1978 Oct;24(10):1751–1754. [PubMed] [Google Scholar]